Form 4 for NKTR NEKTAR THERAPEUTICS
Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-17 · accession 0000950170-24-062646 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-20 | 2024-05-17 | NKTR | ROBIN HOWARD W | Pres, CEO, Dir | S - Sale | $1.75 | -16.6K | 863.2K | -2% | -$29.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-17 | S | D | 16,650 | $1.75 | 863,239 | D | — | — | (F1) Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. (F2) This transaction was executed in multiple trades at prices ranging from $1.72 to $1.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |